Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus OGEN 1 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus OGEN 1 25.
ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST vs OGEN 1.25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
None Documented
None Documented
Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels.
Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days
Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces.
Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5%
Category D/X
Category C
Estrogen
Estrogen